Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

211.61USD
25 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$211.61
Open
$210.12
Day's High
$213.28
Day's Low
$208.05
Volume
3,982,373
Avg. Vol
2,237,123
52-wk High
$256.80
52-wk Low
$184.50

Latest Key Developments (Source: Significant Developments)

Allergan to acquire eye care company Forsight Vision5
Thursday, 11 Aug 2016 08:00am EDT 

Allergan PLC : Allergan to acquire eye care company Forsight Vision5 adding Peri-Ocular Ring Technology to company's leading portfolio of innovative eye health products . Under terms of agreement, Allergan will acquire Forsight Vision5 for a $95 million upfront payment and a launch milestone payment .Transaction is expected to be completed within 60 days.  Full Article

Allergan Equico reports 9.9 pct stake in Teva Pharmaceutical
Monday, 8 Aug 2016 06:15pm EDT 

Allergan :Reports a stake of 9.9 pct in Teva Pharmaceutical Industries Ltd as of July 27, 2016 - SEC filing.  Full Article

Allergan reports Q2 non-GAAP earnings per share of $3.35
Monday, 8 Aug 2016 07:00am EDT 

Allergan Plc : Allergan reports strong second quarter 2016 continuing operations performance with net revenues of $3.7 billion . Q2 revenue $3.7 billion . Company updates full-year 2016 continuing operations guidance . Q2 non-GAAP earnings per share $3.35 . Q2 loss per share $1.25 from continuing operations . Q2 earnings per share view $3.34 -- Thomson Reuters I/B/E/S . Sees full year GAAP and non-GAAP total reported net revenue $14.65 billion - $14.90 billion . Sees FY total branded net revenue $14.75 bln - $15 bln . Sees FY 2016 GAAP loss per share $1.95 - $2.15; sees FY 2016 non-GAAP earnings per share $13.75 - $14.20 . FY 2016 earnings per share view $14.19 -- Thomson Reuters I/B/E/S .Total net revenues in quarter were impacted by "loss of exclusivity on Namenda IR".  Full Article

Allergan Q2 non-GAAP earnings per share $3.35
Monday, 8 Aug 2016 07:00am EDT 

Allergan Plc : Allergan reports strong second quarter 2016 continuing operations performance with net revenues of $3.7 billion . Q2 non-GAAP earnings per share $3.35 . Q2 loss per share $1.25 from continuing operations . Q2 revenue $3.7 billion versus i/b/e/s view $4.08 billion . Q2 earnings per share view $3.34 -- Thomson Reuters I/B/E/S . GAAP total reported net revenues $14.65 billion - $14.90 billion . Total net revenues in quarter were impacted by "loss of exclusivity on Namenda IR" . Company updates full-year 2016 continuing operations guidance . Sees full-year total branded net revenue $14.75 billion- $15 billion . Sees 2016 GAAP loss per share of $1.95 - $2.15; sees 2016 non GAAP earnings per share of $13.75 - $14.20 .Full-year 2016 earnings per share view $14.19, revenue view $16.61 billion -- Thomson Reuters I/B/E/S.  Full Article

Allergan has no interest in a Biogen deal - CNBC, citing sources
Wednesday, 3 Aug 2016 09:38am EDT 

:Allergan has no interest in a Biogen deal - CNBC, citing sources.  Full Article

Allergan announces sale of Anda distribution business to Teva
Wednesday, 3 Aug 2016 07:00am EDT 

Allergan Plc : For Q2 of 2016, Anda is expected to contribute approximately $375 million in net revenues excluding sales of Allergan's branded products . For Q2 of 2016, Anda is expected to contribute approximately $0.05 in earnings per share . Allergan announces sale of Anda distribution business to Teva Pharmaceuticals . Allergan Plc says deal valued at $500 million . Anda to be reported as discontinued operations beginning with Q2 2016 earnings report on August 8, 2016 .For full year 2016, Anda is expected to contribute approximately $1.5 billion in third-party net revenue and approximately $0.15 in EPS.  Full Article

Allergan unlikely to pursue Biogen deal- CNBC,citing source
Tuesday, 2 Aug 2016 04:15pm EDT 

: Allergan unlikely to pursue Biogen deal- CNBC,citing source (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Allergan completes divestiture of global generics business to Teva Pharmaceuticals
Tuesday, 2 Aug 2016 12:41pm EDT 

Allergan PLC : Allergan PLC completes divestiture of Global Generics Business to Teva Pharmaceuticals . Company to provide updated guidance as part of Q2 2016 earnings . Plans to commence its previously announced share repurchase program of up to $10 billion of company's common stock in coming days .Company expects to execute an initial $5 billion in open market repurchases over remainder of 2016.  Full Article

Teva gets U.S. FTC clearance for Actavis Generics deal
Wednesday, 27 Jul 2016 02:36pm EDT 

Teva Pharmaceutical Industries Ltd : Teva receives clearance from the U.S. Federal Trade Commission for Actavis Generics acquisition . Has satisfied regulatory approval requirements under purchase agreement to complete acquisition of Actavis Generics .Transaction is expected to close next week.  Full Article

Allergan receives positive opinion for its treatment for IBS-D in adults
Monday, 25 Jul 2016 11:30am EDT 

Allergan Plc : Allergan receives positive opinion for Truberzi® (eluxadoline) for treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults . Truberzi® was generally well tolerated with most common side effects being nausea, constipation, and abdominal pain . Final decision from European Commission on Truberzi is expected within a few months .If approved, anticipate launching Truberzi in Europe during 2017, following negotiations with relevant national payer,reimbursement groups.  Full Article

Photo

Allergan boosts shares with $2 billion buyback

U.S. drugmaker Allergan Plc on Monday authorized a $2 billion buyback of its common stock, sending its shares up after a week of disappointing news on its drug development pipeline.